Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company dedicated to developing gene therapies to restore vision and avert blindness from inherited retinal diseases (IRDs), has announced its participation in a series of prominent ophthalmology and industry conferences in February 2026. The company’s leadership team will be actively engaged in discussions aimed at fostering innovation and sharing insights on treatment approaches for retinal diseases.

The first event is the Collaborative Community on Ophthalmic Innovation (CCOI) conference, taking place on February 3-4 in Hong Kong. Here, Opus will delve into emerging treatment modalities and clinical insights in retinal disease. Following this, at the Asia-Pacific Academy of Ophthalmology Congress (APAO) from February 5-8, Opus will engage with the global ophthalmology community to present advancements in gene therapy specifically for inherited retinal disorders.

On February 11, Chris Ernst, Chief Technology Officer of Opus Genetics, will speak at the Advanced Therapies Week Conference in San Diego, covering scalable viral vector manufacturing models, which are critical for gene therapy production. Lastly, during The Macula Society Annual Meeting on February 27, Dr. Mark Pennesi will present preliminary results from the phase 1b/2a clinical study of OPGx-BEST1 gene therapy for treating Best vitelliform macular dystrophy (BVMD) resulting from BEST1 mutations.

With a robust pipeline focusing on durable one-time treatments for severe retinal disorders, including seven AAV-based programs, Opus Genetics stands at the forefront of innovative solutions for patients with inherited retinal diseases. The company is headquartered in Research Triangle Park, NC, and aims to address genetic causes of vision impairment comprehensively. For further details, visit their website at www.opusgtx.com.

As Opus Genetics (Nasdaq: IRD) approaches a series of key medical and industry conferences throughout February 2026, investors should closely monitor the potential implications of these events for the company’s market performance. With a focus on gene therapies aimed at treating inherited retinal diseases (IRDs), Opus Genetics is well-positioned to capitalize on growing interest in ophthalmological innovations and advanced treatment models.

These upcoming events, notably the Collaborative Community on Ophthalmic Innovation (CCOI), the Asia-Pacific Academy of Ophthalmology (APAO) Congress, and the Advanced Therapies Week, will provide a platform for Opus’s leadership to share insights on their innovative gene therapies—particularly OPGx-BEST1 and OPGx-LCA5. Attendance and presentations at these prestigious forums will enhance the company's visibility amongst key stakeholders and may stimulate collaborations, potentially paving the way for strategic partnerships and increased funding opportunities.

Additionally, the dissemination of preliminary clinical data, such as the results from the Phase 1b/2a study of the OPGx-BEST1 gene therapy during The Macula Society Annual Meeting, could significantly influence investor sentiment. Positive data releases can substantively boost stock prices as they validate the efficacy and safety of Opus’s therapies, thereby attracting more investor interest.

Investors should consider accumulating shares ahead of these events, particularly if market sentiment remains bullish on gene therapy advancements. This could present a strategic opportunity as the company raises its profile within the ophthalmic community and seeks to establish itself as a leader in the treatment of IRDs.

Given the transformative potential of Opus Genetics' pipeline and upcoming presentations, maintaining a favorable outlook while carefully monitoring conference outcomes will be essential for informed investment decisions in the coming weeks.